Outlive
LongevityResearchHub

Interactions between dietary intake and GLP-1 biology: implications for metabolic dysfunction and aging.

TL;DR

Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as highly effective therapies for obesity and type 2 diabetes by improving glycemic control and reducing body weight, primarily through the suppression of energy intake. Recent evidence suggests a bidirectional relationship between dietary intake and GLP-1 biology. Dietary factors, including caloric intake, meal timing, and macronutrient composition, may influence endogenous GLP-1 secretion, while GLP-1-based therapies may alter food

Credibility Assessment Preliminary — 46/100
Study Design
Rigor of the research methodology
5/20
Sample Size
Whether the study was sufficiently powered
7/20
Peer Review
Review status and journal reputation
18/20
Replication
Has this finding been independently reproduced?
6/20
Transparency
Funding disclosure and data availability
10/20
Overall
Sum of all five dimensions
46/100

Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as highly effective therapies for obesity and type 2 diabetes by improving glycemic control and reducing body weight, primarily through the suppression of energy intake. Recent evidence suggests a bidirectional relationship between dietary intake and GLP-1 biology. Dietary factors, including caloric intake, meal timing, and macronutrient composition, may influence endogenous GLP-1 secretion, while GLP-1-based therapies may alter food choice and macronutrient preference. This review discusses the effects of dietary intake on endogenous GLP-1 regulation and examines how GLP-1-based therapies influence ingestive behavior and food preference, with particular emphasis on the responses to macronutrient composition. We further discuss the potential interaction between dietary intake and pharmacological GLP-1 signaling and its implications for metabolic health and aging. A better understanding of these bidirectional interactions may contribute to the development of personalized nutritional approaches that complement GLP-1-based therapies and improve long-term management of metabolic dysfunction.

View Original Source

0 Comments